Company profile: Evolutionary Genomics
1.1 - Company Overview
Company description
- Provider of a proprietary Adapted Traits platform for molecular evolution analysis to identify and validate genes impacting commercially valuable crop traits, including yield, pest resistance, and drought tolerance; offering R&D services and patented genes such as FusR1 for banana Panama disease resistance and EG261 for soybean cyst nematode resistance; collaborating on cassava brown streak disease resistance with the Bill and Melinda Gates Foundation.
Products and services
- Adapted Traits Platform: A proprietary molecular evolution analysis system that sifts vast genomic datasets to identify crop genes tied to commercially valuable traits like yield, drought tolerance, and pest resistance
- FusR1 Gene Patent for Banana Disease Resistance: A patented wild-banana gene offering resistance to Panama disease, potentially saving the global banana industry from devastating losses
- Gene Identification and Validation: Research-grade R&D services that identify and validate crop genes influencing yield, pest resistance, and drought tolerance, across various crops using EG’s post-genomics discovery approach
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Evolutionary Genomics
Counsyl
HQ: United States
Website
- Description: Provider of DNA screening for men, women, and their children, focusing on diseases where advanced knowledge can improve health outcomes, whether by changing behavior, pursuing preventative measures, or preparing for what lies ahead.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Counsyl company profile →
Rome Therapeutics
HQ: United States
Website
- Description: Provider of novel therapies for cancer and autoimmune diseases harnessing the repeatome, including development of LINE-1 reverse transcriptase inhibitors for autoimmune diseases, supported by a data science platform that identifies active elements in the dark genome and assesses their roles in disease to guide drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rome Therapeutics company profile →
Syros
HQ: United States
Website
- Description: Provider of a gene control platform that systematically analyzes regulatory regions of the genome to develop small-molecule medicines that control gene expression, and developer of oral therapeutics including tamibarotene (selective RARα agonist) in clinical development for genomically defined HR-MDS and AML, and previously clinical assets SY-2101 (oral arsenic trioxide for APL) and SY-5609 (CDK7 inhibitor for pancreatic cancer).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syros company profile →
QuanDx
HQ: United States
Website
- Description: Provider of life science reagents and molecular diagnostic kits, including the Q-Fusion multiplex system and Q30 screening kit for leukemia fusion genes, Yin-Yang Probes for affordable, multiplexed tests for various diseases, and a High Risk HPV Genotyping Assay detecting 14 types of high-risk HPV with automatic result interpretation in a single tube reaction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QuanDx company profile →
Delfi Diagnostics
HQ: United States
Website
- Description: Provider of high-precision, non-invasive blood tests for early cancer detection, including the FirstLook Lung test using DNA fragment patterns; leverages machine learning and fragmentomics to analyze cell-free DNA fragments; and runs the CASCADE-LUNG clinical study to validate blood-based lung cancer screening technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delfi Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Evolutionary Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Evolutionary Genomics
2.2 - Growth funds investing in similar companies to Evolutionary Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Evolutionary Genomics
4.2 - Public trading comparable groups for Evolutionary Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →